Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2001 Jan;77(903):4–10. doi: 10.1136/pmj.77.903.4

Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management

M Kearney 1, J Cotton 1, P Richardson 1, A Shah 1
PMCID: PMC1741887  PMID: 11123385

Abstract

Viral infection of the heart is relatively common and usually of little consequence. It can, however, lead to substantial cardiac damage and severe acute heart failure. It can also evolve into the progressive syndrome of chronic heart failure. Recent studies have gone some way towards unravelling the complex mechanisms underlying the heart muscle damage that occurs after viral infection. These studies have lent support to both immune and viral mediated (independent of an immune response) cardiac damage. Acute myocarditis can present in various ways, and it may be a cause of sudden death in an otherwise healthy young adult. New treatments for viral heart disease are awaited. In the meanwhile, the haemodynamic support of patients with acute left ventricular failure caused by myocarditis should be aggressive, to allow for the possibility of spontaneous recovery. Contemporary trials of treatment in chronic heart failure secondary to dilated cardiomyopathy support the use of angiotensin converting enzyme inhibitors, β adrenoceptor blockers, and spironolactone in such patients.


Keywords: myocarditis; heart failure; coxsackie B virus; dilated cardiomyopathy

Full Text

The Full Text of this article is available as a PDF (206.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aretz H. T., Billingham M. E., Edwards W. D., Factor S. M., Fallon J. T., Fenoglio J. J., Jr, Olsen E. G., Schoen F. J. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987 Jan;1(1):3–14. [PubMed] [Google Scholar]
  2. Badorff C., Lee G. H., Lamphear B. J., Martone M. E., Campbell K. P., Rhoads R. E., Knowlton K. U. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999 Mar;5(3):320–326. doi: 10.1038/6543. [DOI] [PubMed] [Google Scholar]
  3. Barbaro G., Di Lorenzo G., Grisorio B., Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med. 1998 Oct 15;339(16):1093–1099. doi: 10.1056/NEJM199810153391601. [DOI] [PubMed] [Google Scholar]
  4. Beckman J. S., Koppenol W. H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996 Nov;271(5 Pt 1):C1424–C1437. doi: 10.1152/ajpcell.1996.271.5.C1424. [DOI] [PubMed] [Google Scholar]
  5. Chandraratna P. A., Nimalasuriya A., Reid C. L., Cohn S., Rahimtoola S. H. Left ventricular asynergy in acute myocarditis. Simulation of acute myocardial infarction. JAMA. 1983 Sep 16;250(11):1428–1430. [PubMed] [Google Scholar]
  6. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  7. Costanzo-Nordin M. R., O'Connell J. B., Subramanian R., Robinson J. A., Scanlon P. J. Myocarditis confirmed by biopsy presenting as acute myocardial infarction. Br Heart J. 1985 Jan;53(1):25–29. doi: 10.1136/hrt.53.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Drory Y., Turetz Y., Hiss Y., Lev B., Fisman E. Z., Pines A., Kramer M. R. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991 Nov 15;68(13):1388–1392. doi: 10.1016/0002-9149(91)90251-f. [DOI] [PubMed] [Google Scholar]
  9. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992 Sep 3;327(10):685–691. doi: 10.1056/NEJM199209033271003. [DOI] [PubMed] [Google Scholar]
  10. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug 1;325(5):293–302. doi: 10.1056/NEJM199108013250501. [DOI] [PubMed] [Google Scholar]
  11. Ferdeghini E. M., Pinamonti B., Picano E., Lattanzi F., Bussani R., Slavich G., Benassi A., Camerini F., Landini L., L'Abbate A. Quantitative texture analysis in echocardiography: application to the diagnosis of myocarditis. J Clin Ultrasound. 1991 Jun;19(5):263–270. doi: 10.1002/jcu.1870190503. [DOI] [PubMed] [Google Scholar]
  12. Figulla H. R., Stille-Siegener M., Mall G., Heim A., Kreuzer H. Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995 Apr;25(5):1170–1175. doi: 10.1016/0735-1097(94)00517-t. [DOI] [PubMed] [Google Scholar]
  13. GIBSON T. C., ARNOLD J., CRAIGE E., CURNEN E. C. Electrocardiographic studies in Asian influenza. Am Heart J. 1959 May;57(5):661–668. doi: 10.1016/0002-8703(59)90175-9. [DOI] [PubMed] [Google Scholar]
  14. GRODUMS E. I., DEMPSTER G. The age factor in experimental Coxsackie B-3 infection. Can J Microbiol. 1959 Dec;5:595–604. doi: 10.1139/m59-073. [DOI] [PubMed] [Google Scholar]
  15. Gatmaitan B. G., Chason J. L., Lerner A. M. Augmentation of the virulence of murine coxsackie-virus B-3 myocardiopathy by exercise. J Exp Med. 1970 Jun 1;131(6):1121–1136. doi: 10.1084/jem.131.6.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hirono S., Islam M. O., Nakazawa M., Yoshida Y., Kodama M., Shibata A., Izumi T., Imai S. Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. Circ Res. 1997 Jan;80(1):11–20. doi: 10.1161/01.res.80.1.11. [DOI] [PubMed] [Google Scholar]
  17. Hosenpud J. D., Novick R. J., Bennett L. E., Keck B. M., Fiol B., Daily O. P. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report--1996. J Heart Lung Transplant. 1996 Jul;15(7):655–674. [PubMed] [Google Scholar]
  18. Huber S. A., Job L. P., Auld K. R. Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice. Cell Immunol. 1982 Feb;67(1):173–179. doi: 10.1016/0008-8749(82)90210-6. [DOI] [PubMed] [Google Scholar]
  19. Huber S. A., Lodge P. A. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am J Pathol. 1984 Jul;116(1):21–29. [PMC free article] [PubMed] [Google Scholar]
  20. Ishiyama S., Hiroe M., Nishikawa T., Abe S., Shimojo T., Ito H., Ozasa S., Yamakawa K., Matsuzaki M., Mohammed M. U. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 1997 Jan 21;95(2):489–496. doi: 10.1161/01.cir.95.2.489. [DOI] [PubMed] [Google Scholar]
  21. Karjalainen J. Functional and myocarditis-induced T-wave abnormalities. Effect of orthostasis, beta-blockade, and epinephrine. Chest. 1983 Jun;83(6):868–874. doi: 10.1378/chest.83.6.868. [DOI] [PubMed] [Google Scholar]
  22. Karjalainen J., Nieminen M. S., Heikkilä J. Influenza A1 myocarditis in conscripts. Acta Med Scand. 1980;207(1-2):27–30. doi: 10.1111/j.0954-6820.1980.tb09670.x. [DOI] [PubMed] [Google Scholar]
  23. Karjalainen J., Viitasalo M., Kala R., Heikkilä J. 24-Hour electrocardiographic recordings in mild acute infectious myocarditis. Ann Clin Res. 1984;16(1):34–39. [PubMed] [Google Scholar]
  24. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999 Mar 2;99(8):1091–1100. doi: 10.1161/01.cir.99.8.1091. [DOI] [PubMed] [Google Scholar]
  25. Kelly R. A., Balligand J. L., Smith T. W. Nitric oxide and cardiac function. Circ Res. 1996 Sep;79(3):363–380. doi: 10.1161/01.res.79.3.363. [DOI] [PubMed] [Google Scholar]
  26. Kelly R. A., Balligand J. L., Smith T. W. Nitric oxide and cardiac function. Circ Res. 1996 Sep;79(3):363–380. doi: 10.1161/01.res.79.3.363. [DOI] [PubMed] [Google Scholar]
  27. Kishimoto C., Kuribayashi K., Masuda T., Tomioka N., Kawai C. Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation. 1985 Jun;71(6):1247–1254. doi: 10.1161/01.cir.71.6.1247. [DOI] [PubMed] [Google Scholar]
  28. Knowlton K. U., Badorff C. The immune system in viral myocarditis: maintaining the balance. Circ Res. 1999 Sep 17;85(6):559–561. doi: 10.1161/01.res.85.6.559. [DOI] [PubMed] [Google Scholar]
  29. Kojima J., Miyazaki S., Fujiwara H., Kumada T., Kawai C. Recurrent left ventricular mural thrombi in a patient with acute myocarditis. Heart Vessels. 1988;4(2):120–122. doi: 10.1007/BF02059000. [DOI] [PubMed] [Google Scholar]
  30. Lodge P. A., Herzum M., Olszewski J., Huber S. A. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol. 1987 Sep;128(3):455–463. [PMC free article] [PubMed] [Google Scholar]
  31. Mason J. W., O'Connell J. B., Herskowitz A., Rose N. R., McManus B. M., Billingham M. E., Moon T. E. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995 Aug 3;333(5):269–275. doi: 10.1056/NEJM199508033330501. [DOI] [PubMed] [Google Scholar]
  32. Matsumori A. Molecular and immune mechanisms in the pathogenesis of cardiomyopathy--role of viruses, cytokines, and nitric oxide. Jpn Circ J. 1997 Apr;61(4):275–291. doi: 10.1253/jcj.61.275. [DOI] [PubMed] [Google Scholar]
  33. McNamara D. M., Rosenblum W. D., Janosko K. M., Trost M. K., Villaneuva F. S., Demetris A. J., Murali S., Feldman A. M. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 1997 Jun 3;95(11):2476–2478. doi: 10.1161/01.cir.95.11.2476. [DOI] [PubMed] [Google Scholar]
  34. Mikami S., Kawashima S., Kanazawa K., Hirata K., Katayama Y., Hotta H., Hayashi Y., Ito H., Yokoyama M. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochem Biophys Res Commun. 1996 Mar 27;220(3):983–989. doi: 10.1006/bbrc.1996.0519. [DOI] [PubMed] [Google Scholar]
  35. Nishio R., Matsumori A., Shioi T., Ishida H., Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation. 1999 Sep 7;100(10):1102–1108. doi: 10.1161/01.cir.100.10.1102. [DOI] [PubMed] [Google Scholar]
  36. O'Connell J. B., Costanzo-Nordin M. R., Subramanian R., Robinson J. A., Wallis D. E., Scanlon P. J., Gunnar R. M. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986 Jul;8(1):52–56. doi: 10.1016/s0735-1097(86)80091-2. [DOI] [PubMed] [Google Scholar]
  37. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist. Circulation. 1999 Oct 26;100(17):1823–1829. doi: 10.1161/01.cir.100.17.1823. [DOI] [PubMed] [Google Scholar]
  38. Opavsky M. A., Penninger J., Aitken K., Wen W. H., Dawood F., Mak T., Liu P. Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection. Circ Res. 1999 Sep 17;85(6):551–558. doi: 10.1161/01.res.85.6.551. [DOI] [PubMed] [Google Scholar]
  39. Paulus W. J., Vantrimpont P. J., Shah A. M. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994 May;89(5):2070–2078. doi: 10.1161/01.cir.89.5.2070. [DOI] [PubMed] [Google Scholar]
  40. Paulus W. J., Vantrimpont P. J., Shah A. M. Paracrine coronary endothelial control of left ventricular function in humans. Circulation. 1995 Oct 15;92(8):2119–2126. doi: 10.1161/01.cir.92.8.2119. [DOI] [PubMed] [Google Scholar]
  41. Pauschinger M., Phan M. D., Doerner A., Kuehl U., Schwimmbeck P. L., Poller W., Kandolf R., Schultheiss H. P. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999 Feb 23;99(7):889–895. doi: 10.1161/01.cir.99.7.889. [DOI] [PubMed] [Google Scholar]
  42. Pinamonti B., Alberti E., Cigalotto A., Dreas L., Salvi A., Silvestri F., Camerini F. Echocardiographic findings in myocarditis. Am J Cardiol. 1988 Aug 1;62(4):285–291. doi: 10.1016/0002-9149(88)90226-3. [DOI] [PubMed] [Google Scholar]
  43. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  44. Prendergast B. D., Sagach V. F., Shah A. M. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation. 1997 Aug 19;96(4):1320–1329. doi: 10.1161/01.cir.96.4.1320. [DOI] [PubMed] [Google Scholar]
  45. Richardson P. J. King's endomyocardial bioptome. Lancet. 1974 Apr;1(7859):660–661. doi: 10.1016/s0140-6736(74)93204-8. [DOI] [PubMed] [Google Scholar]
  46. Tomioka N., Kishimoto C., Matsumori A., Kawai C. Mural thrombus in experimental viral myocarditis in mice: relation between thrombosis and congestive heart failure. Cardiovasc Res. 1986 Sep;20(9):665–671. doi: 10.1093/cvr/20.9.665. [DOI] [PubMed] [Google Scholar]
  47. Toshima H., Ohkita Y., Shingu M. Clinical features of acute coxsackie B viral myocarditis. Jpn Circ J. 1979 May;43(5):441–444. doi: 10.1253/jcj.43.441. [DOI] [PubMed] [Google Scholar]
  48. Wessely R., Henke A., Zell R., Kandolf R., Knowlton K. U. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation. 1998 Aug 4;98(5):450–457. doi: 10.1161/01.cir.98.5.450. [DOI] [PubMed] [Google Scholar]
  49. Wessely R., Klingel K., Santana L. F., Dalton N., Hongo M., Jonathan Lederer W., Kandolf R., Knowlton K. U. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest. 1998 Oct 1;102(7):1444–1453. doi: 10.1172/JCI1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Why H. J., Meany B. T., Richardson P. J., Olsen E. G., Bowles N. E., Cunningham L., Freeke C. A., Archard L. C. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994 Jun;89(6):2582–2589. doi: 10.1161/01.cir.89.6.2582. [DOI] [PubMed] [Google Scholar]
  51. Woodruff J. F. Viral myocarditis. A review. Am J Pathol. 1980 Nov;101(2):425–484. [PMC free article] [PubMed] [Google Scholar]
  52. Woodruff J. F., Woodruff J. J. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol. 1974 Dec;113(6):1726–1734. [PubMed] [Google Scholar]
  53. Yamada T., Matsumori A., Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 1994 Feb;89(2):846–851. doi: 10.1161/01.cir.89.2.846. [DOI] [PubMed] [Google Scholar]
  54. Young L. H., Joag S. V., Zheng L. M., Lee C. P., Lee Y. S., Young J. D. Perforin-mediated myocardial damage in acute myocarditis. Lancet. 1990 Oct 27;336(8722):1019–1021. doi: 10.1016/0140-6736(90)92486-2. [DOI] [PubMed] [Google Scholar]
  55. de Belder A. J., Radomski M. W., Why H. J., Richardson P. J., Bucknall C. A., Salas E., Martin J. F., Moncada S. Nitric oxide synthase activities in human myocardium. Lancet. 1993 Jan 9;341(8837):84–85. doi: 10.1016/0140-6736(93)92559-c. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES